
This study investigated dose zzso of zzso administered as a zzso regimen with zzso zzso factor zzso zzso The aim was to define the zzso tolerated dose of zzso and to assess the efficacy of zzso to zzso its zzso Patients with zzso advanced zzso were zzso Six dose levels, zzso at 90 zzso of zzso administered every 2 weeks for four courses were planned with zzso 10 zzso administered for 10 days from the second day of each zzso Six patients were to be entered at each dose level, and escalation to the next level was based upon toxicity zzso Twelve patients were entered, six at dose level 1 (90 zzso and six at dose level 2 zzso zzso zzso defined zzso zzso zzso were noted in one patient at dose level 1 and in five patients at dose level zzso Further dose escalation was not zzso zzso zzso zzso included zzso zzso in two and four patients at dose levels 1 and 2, zzso This study has demonstrated that zzso can be safely administered at 2 week intervals with zzso at a dose of 90 zzso equivalent to the previously reported maximum tolerated dose intensity of 45 zzso zzso was zzso despite the use of zzso 

